Anti-diabetic activities of Acanthopanax senticosus polysaccharide (ASP) in combination with metformin.
Combination therapy had become very popular currently for the diabetes mellitus and its complications, because of long term unreasonable drug use and adverse reaction to human body. In this study, a polysaccharide (ASP) from the roots of Acanthopanax senticosus was evaluated as an adjuvant with metformin for antidiabetic therapy in alloxan-induced diabetic rats. The result identified ASP plus metformin had a more beneficial promotion for relieving the symptoms of diabetes and reversing liver and kidney damage to normal level than only metfomin administration to diabetic rats. The blood glucose, blood lipid (TC and TG), thiobarbituric acid reactive substances (TBARS), AST, ALT, ALP, total bilirubin, creatinine and urea levels in diabetic rats were decreased by combination of ASP and metformin. Furthermore, the body weight, liver glycogen formation, antioxidant substance (GSH) and antioxidant enzyme (SOD and GPX) levels increased evidently in diabetic mice treated with both ASP and metformin. In particular, sometimes ASP plus metformin could significantly reverse the pathophysiologic parameters of diabetic rats to normal level than only metformin administration. Therefore ASP could be developed to a new adjuvant combined with metformin for diabetes mellitus therapy in the future.
Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Jianfang
J
Fu
Jufang
J
Fu
Jun
J
Yuan
Nanyan
N
Zhang
Bin
B
Gao
Guoqiang
G
Fu
Yanyang
Y
Tu
Yongsheng
Y
Zhang
D000818:Animals; D001663:Bilirubin / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism; D004347:Drug Interactions; D028001:Eleutherococcus / Q000737:chemistry*; D005978:Glutathione / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008297:Male; D008687:Metformin / Q000494:pharmacology*; D011134:Polysaccharides / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014508:Urea / Q000097:blood
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D008055:Lipids; D011134:Polysaccharides; D017392:Thiobarbituric Acid Reactive Substances; D014508:Urea; D006003:Glycogen; D008687:Metformin; D003404:Creatinine; D005978:Glutathione; D001663:Bilirubin